Stay updated on Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    A site-wide banner announces an NIH terminology transition, noting that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-25T22:42:14.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer revision identifier advanced from v3.7.1 to v3.7.2 on the page displaying a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T22:55:11.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T23:08:29.000Z thumbnail image
  4. Check
    40 days ago
    Change Detected
    Summary
    The study record page now displays a 403 Forbidden error, replacing the previous study details and navigation; users will see an error page instead of the trial information.
    Difference
    18%
    Check dated 2026-09-20T20:50:10.000Z thumbnail image
  5. Check
    61 days ago
    Change Detected
    Summary
    A new revision tag v3.6.6 is displayed, replacing v3.6.5. This indicates a routine update to the page's underlying version rather than a substantive change to study details.
    Difference
    0.1%
    Check dated 2026-08-30T21:41:35.000Z thumbnail image
  6. Check
    83 days ago
    Change Detected
    Summary
    The page's platform revision was updated from v3.6.4 to v3.6.5, indicating a maintenance release of the ClinicalTrials.gov interface. This reflects an underlying software update rather than a change to study information.
    Difference
    0.0%
    Check dated 2026-08-09T10:56:33.000Z thumbnail image

Stay in the know with updates to Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.